Respiratory
Latest news
233 articles · 20 / page
Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics
This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards
Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD
A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
Pathophysiological Divergence in Preterm Infants: Early Lung Aeration and Gas Exchange as Predictors of Moderate-to-Severe Bronchopulmonary Dysplasia
A multicentre prospective study reveals that infants developing moderate-to-severe BPD exhibit significant lung aeration and gas exchange deficits as early as day 10, with a critical pathophysiological peak at 26 days of life, regardless of
Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis
An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica
Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi
Histologic Subtype Dictates the Survival Benefit of Guideline-Adherent Lymph Node Dissection in T1N0M0 Lung Adenocarcinoma
A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefi
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation
A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.
Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC
The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che
High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial
The international PROTHOR trial reveals that using higher PEEP and recruitment manoeuvres during one-lung ventilation does not decrease postoperative pulmonary complications compared to a lower PEEP strategy, while notably increasing intrao
Simplifying Pulmonary Embolism Exclusion: Can One Clinical Question Safely Reduce Imaging?
A prospective multicenter study demonstrates that using a single clinical question—whether pulmonary embolism is the most likely diagnosis—to adjust D-dimer thresholds can safely reduce chest imaging by 19% in emergency departments without
Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m
Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial
The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.
Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
Browse by specialty
Open language-specific specialty feeds and department pages.